Articles
21.09.2026
From Global Price Ambition to Local Access Reality...

Pricing research is often treated as a launch-stage exercise focused on testing a target price. But ...

Read more
Articles
09.09.2026
Choosing payer pricing research? Start with the qu...

Different budget pressures create different payer pricing challenges  Healthcare budget pressur...

Read more
Articles
10.08.2026
The Hidden Risk in Pharma Pricing: When Poor Gover...

Pricing strategies rarely fail because of one decision. More often, price potential is gradually ero...

Read more
Webinar
05.08.2026
Decoding Germany’s SHI reform practical impl...

Germany’s SHI reform bill removes some of the most significant AMNOG restrictions introduced in 20...

Read more
Articles
22.07.2026
Defending Price Under HTA Scrutiny: Why Evidence M...

Price ambition is only defensible when the evidence can carry it  Manufacturers can no longer r...

Read more
Articles
06.07.2026
Why Pricing Strategy Must Start Earlier: Linking E...

Pricing strategy is often treated as a launch activity. However, by the time teams begin detailed pr...

Read more
Insider Insights
06.05.2026
Germany’s Draft SHI Reform Bill: Implications fo...

Germany’s draft GKV Contribution Rate Stabilisation Act signals a clearly tighter environment ...

Read more
Articles
30.03.2026
TrumpRx in Focus: Assessing the Implications for ...

Our previous article explored how TrumpRx might influence drug pricing in the US, the potential ...

Read more
Insider Insights
16.02.2026
TrumpRx: Structural Shift or Symbolic Gesture? 

TrumpRx, the most recent direct-to-consumer platform aimed at cutting drug prices for Amer...

Read more
Articles
28.01.2026
If You’re a Market Access Lead in 2026: How to N...

In 2026, U.S. policy shifts will link domestic US prices to internatio...

Read more

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.